Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With “Good Prognosis” Rectal Cancer Eligible for Primary Surgery
Erin Kennedy(Mount Sinai Hospital), Nancy N. Baxter(St. Michael's Hospital), Katerina Neumann(Queen Elizabeth II Health Sciences Centre), Neil Kopek(McGill University Health Centre), Caroline Lavoie(Université Laval), Wei Xiong(Army Medical University), Victoria Marcus(Montreal General Hospital), Caroline Reinhold(McGill University Health Centre), Alexandre Bouchard(Ottawa Hospital), Thomas Arnason(Dalhousie University), Sharon E. Clarke(Queen Elizabeth II Health Sciences Centre), Patrick M. Vos(University of British Columbia), Kartik Jhaveri, Nikhilesh Patil(Tata Memorial Hospital), Sébastien Drolet(Université Laval), Gil Chow(North York General Hospital), Richard Kirsch(University of Toronto), Stanislas HX Morin(Université Laval), Catherine O′Brien(University Health Network), Selina Schmocker(Mount Sinai Hospital), Marko Šimunović, Gina Brown(Imperial College Healthcare NHS Trust), Lara Williams(Ottawa Hospital), Raimond Wong(Juravinski Cancer Centre), Robin S. McLeod(University of Toronto), Peter Stotland(North York General Hospital), Ann Wright(Centre hospitalier universitaire de Québec), Jim Brierley(University of Toronto), Cathy Streutker(St. Michael's Hospital), Selliah Kanthan(University of Saskatchewan), Charles Cho(University Health Network), Sender Liberman(McGill University), Simon Raphael(North York General Hospital), Alex Mathieson(Memorial University of Newfoundland), Tony MacLean(University of Calgary), Carl J. Brown(University of British Columbia), Martine Périgny(Université Laval), Amandeep Pooni(Mount Sinai Hospital)
Cited by 117
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
|Journal of Clinical Oncology|2013|841
Immediate and long-term impact of the COVID-19 pandemic on delivery of surgical services
|British journal of surgery|2020|719